101.114-24/03 – including *Taq* pol., IFU-01 **101.114-24**u/**03**u – without *Taq* pol., IFU-02

Visit <u>www.olerup-ssp.com</u> for "Instructions for Use" (IFU)

Lot No.: 33R

Lot-specific information

CERTIFICATE OF ANALYSIS

Olerup SSP® DRB1*04 SSP

Product number: 101.114-24/03 – including *Taq* pol.

101.114-24u/03u - without Tag pol.

Lot number: 33R

Expiry date: 2015-April-01

Number of tests: 24 tests – Product No. 101.114-24/24u

3 tests - Product No. 101.114-03/03u

Number of wells per test: 47

Well specifications:

Well No.	Production No.	Well No.	Production No.	Well No.	Production No.
1	2011-881-01	17	2011-881-17	33	2011-881-33
2	2011-881-02	18	2011-881-18	34	2011-881-34
3	2011-881-03	19	2011-881-19	35	2011-881-35
4	2011-881-04	20	2011-881-20	36	2012-076-36
5	2011-881-05	21	2012-076-21	37	2011-881-37
6	2011-881-06	22	2011-881-22	38	2011-881-38
7	2011-881-07	23	2012-076-23	39	2011-881-39
8	2011-881-08	24	2012-076-24	40	2011-881-40
9	2011-881-09	25	2011-881-25	41	2011-881-41
10	2011-881-10	26	2011-881-26	42	2012-076-42
11	2011-881-11	27	2011-881-27	43	2012-076-43
12	2011-881-12	28	2011-881-28	44	2012-076-44
13	2011-881-13	29	2011-881-29	45	2012-076-45
14	2012-076-14	30	2011-881-30	46	2012-076-46
15	2011-881-15	31	2011-881-31	47	2012-076-47
16	2012-076-16	32	2011-881-32		

The specificity of each primer solution of the kit has been tested against 48 well characterized IHWC cell line DNAs.

No DNAs carrying the alleles to be amplified by primer solutions 11, 13, 15, 17 to 20, 22, 23, 25 and 33 to 47 were available. The specificities of the primers in primer solutions 11, 13, 17 to 20, 35, 37 to 39, 42 and 45 were tested by separately adding one additional 5'-primer, respectively, one additional 3'-primer.

In primer solutions 15, 23, 25, 34 and 36 it was only possible to test the 3'-primers, the 5'-primers were not possible to test.

In primer solutions 22, 33, 40, 41, 43, 44, 46 and 47 it was only possible to test the 5'-primers, the 3'-primers were not possible to test.

One or two of the 3'-primers in primer solutions 10, 12 to 14, 17, 19 to 21, 26, 32, 35, 38, 39 and 42 was not possible to test, and in primer solution 27, 29 and 31 one or two 5'-primers was not possible to test.

One additional 3'-primer in primer solution 21 was tested by separately adding one additional 5'-primer.

101.114-24/03 - including Taq pol., IFU-01 101.114-24u/03u - without Taq pol., IFU-02

Visit www.olerup-ssp.com for "Instructions for Use" (IFU)

Lot No.: 33R

Lot-specific information

Results:

No false positive or false negative amplifications were obtained.

Date of approval: 2012-October-25

Dea Olaussun

Approved by:

Production Quality Control

101.114-24/03 – including *Taq* **pol.,** IFU-01 **101.114-24u/03u – without** *Taq* **pol.,** IFU-02

Visit <u>www.olerup-ssp.com</u> for "Instructions for Use" (IFU)

Lot No.: 33R Lot-specific information

Declaration of Conformity

Product name:
Product number:

Olerup SSP® DRB1*04 101.114-24/24u, 03/03u

Lot number:

33R

Intended use:

DRB1*04 high resolution histocompatibility testing

Manufacturer:

Olerup SSP AB Franzengatan 5

SE-112 51 Stockholm, Sweden

Phone: +46-8-717 88 27 **Fax:** +46-8-717 88 18

We, *Olerup* SSP AB, hereby declare that this product, to which this Declaration of Conformity relates is in conformity with the following Standard(s) and other normative document(s) ISO 9001:2008 and ISO 13485:2003, following the provisions of the 98/79/EC Directive on *in vitro* diagnostic medical devices, Annex II List B, conformity assessed using Annex IV, as transposed into the national laws of the Member States of the European Union.

The Technical Documentation File is maintained at *Olerup* SSP AB, Franzengatan 5, SE-112 51 Stockholm, Sweden.

The Authorized Representative located within the Community is: Olerup SSP AB.

Notified Body: Lloyd's Register Quality Assurance Limited, Hiramford, Middlemarch Office Village, Siskin Drive, Coventry CV3 4FJ, United Kingdom. (Notified Body number: 0088.)

Stockholm, Sweden 2012-October-25

Ann-Cathrin Jareman

a-120

Head of QA and Regulatory Affairs